

QTERNMET XR - (2.5MG;1000MG;2.5MG, 5MG;1000MG;2.5MG, 5MG;1000MG;5MG, 10MG;1000MG;5MG ; TABLET,EXTENDED RELEASE)

| | | | |
|------------------------------|---|-----------------------------|---------------------|
| Generic Name | DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE | Innovator | Astrazeneca |
| Dosage | 2.5MG;1000MG;2.5MG, 5MG;1000MG;2.5MG, 5MG;1000MG;5MG, 10MG;1000MG;5MG ; TABLET,EXTENDED RELEASE | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | None | Known Para IV Filers | None |
| Other ANDA developers | None | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | QTERNMET XR is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, a dipeptidyl peptidase-4 (DPP-4) inhibitor and a biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.